Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies
| Autor: | H.L. Parnes, L. Linderberg, Tina Moore, M. Aviles, Mark N. Stein, Amir Mortazavi, Rene Costello, D.P. Bottaro, M. Berniger, W. L. Dahut, N. Davarpanah, Sumanta K. Pal, J. Lin, Andrea B. Apolo, Rosa Nadal, Y.M. Ning, Lisa M. Cordes, Tiffany Lancaster, Seth M. Steinberg, M. Bagheri |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty Metastatic Urothelial Carcinoma CARCINOMA TRANSITIONAL CELL Cabozantinib business.industry Genitourinary system Ipilimumab Hematology Phase i study 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine chemistry 030220 oncology & carcinogenesis Internal medicine medicine 030211 gastroenterology & hepatology In patient Nivolumab business medicine.drug |
| Zdroj: | Annals of Oncology. 28:v295 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdx371.001 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|